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Re: Antidepressant Pretreatment and Symptomatic Treatment in Interferon Treatment
Dear Editor:
We thank Dr Wiwanitkit for his interest in our review article published in The Canadian Journal of Psychiatry last year. We agree with Dr Wiwanitkit's statement that preventative antidepressant (AD) treatment for interferon-alpha-induced major depressive depression (IFN-MDD) remains controversial and feel it is important to clarify the difference between AD pretreatment and preventative (prophylactic) AD treatment when discussing this issue. At the present time, we have sufficient evidence arguing against universal AD pretreatment to prevent IFN-MDD in patients who are at low risk of neuropsychiatric side effects. The conclusions of De Bie et al 1 in 2005 predate the 2 recently published randomized controlled trials of AD pretreatment in preventing IFN-MDD, which failed to demonstrate significant benefit with prophylactic therapy. 2, 3 In addition, Kraus et al 4 found that that IFN-MDD responds well to citalopram and mood improvement can be observed as early as 2 weeks after initiating AD treatment. Therefore, findings from these studies argue against universal AD pre-treatment in hepatitis C virus (HCV) patients, especially in patients with no significant psychopathology prior to starting interferon-alpha (IFNa) treatment.
In contrast, we suggest that AD pretreatment could be beneficial for a select group of HCV patients who are at high risk for IFN-MDD. This high-risk group includes patients with elevated baseline depressive symptoms prior to IFNa therapy and a history of IFN-MDD. 5, 6 Further, Dr Wiwanitkit suggests that agents other than selective serotonin reuptake inhibitors may be beneficial and cites a case report of methylphenidate used to treat neurovegetative symptoms in a patient with malignant melanoma. The use of data from malignant melanoma patient populations receiving INFa is problematic, as malignant melanoma patients require higher doses of IFNa therapy and study findings have not generalized to HCV patients. 2, 3, 7 We agree that further studies exploring other therapeutic options for IFN-MDD in HCV patients are needed.
We thank Dr Wiwanitkit for his interest in our article and agree that further research is needed in this area.
